Survivin polymorphism is associated with disease activity in rheumatoid arthritis patients

Pharmacogenomics

Volumn , Issue 1, 2016, Pages 37-45

  Jenko, Barbara ^a   Praprotnik, Sonja ^b   Čučnik, Saša ^b   Rotar, Žiga ^b   Tomšič, Matija ^a,b   Dolžan, Vita ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

genetic polymorphism; methotrexate; rheumatoid arthritis; survivin

Indexed keywords

BIRC5 PROTEIN; CYSTEINE; GLYCINE; METHOTREXATE; SURVIVIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ALLELE; ARTICLE; BIRC5 GENE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROMOTER REGION; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; WILD TYPE; ARTHRITIS, RHEUMATOID; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; FEMALE; GENOTYPE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; METHOTREXATE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES;

EID: 84952649643     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.147     Document Type: Article

References (27)

1. Smith MD, Weedon H, Papangelis V et al. Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatology (Oxford) 49(5), 862-875 (2010).
2. Umicevic Mirkov M, Cui J, Vermeulen SH et al. Genomewide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann. Rheum. Dis. 72(8), 1375-1381 (2013).
3. Bokarewa M, Lindblad S, Bokarew D, Tarkowski A. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res. Ther. 7(2), R349-R358 (2005).
4. Galeotti L, Adrian K, Berg S, Tarkowski A, Bokarewa M. Circulating survivin indicates severe course of juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 26(2), 373-378 (2008).
5. Svensson B, Hafstrom I, Forslind K et al. Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis. Ann. Med. 42(1), 45-54 (2010).
6. Ahn JK, Oh JM, Lee J et al. Increased extracellular survivin in the synovial fluid of rheumatoid arthritis patients: fibroblast-like synoviocytes as a potential source of extracellular survivin. Inflammation 33(6), 381-388 (2010).
7. Isgren A, Forslind K, Erlandsson M et al. High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis. Semin. Arthritis Rheum. 41(5), 652-657 (2012).
8. Svensson B, Hafstrom I, Erlandsson MC, Forslind K, Bokarewa MI. Smoking in combination with antibodies to cyclic citrullinated peptides is associated with persistently high levels of survivin in early rheumatoid arthritis: a prospective cohort study. Arthritis Res. Ther. 16(1), R12 (2014).
9. Andersson SEM, Svensson MND, Erlandsson MC et al. Activation of Fms-like tyrosine Kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis. PLoS ONE 7(10), e47668 (2012).
10. Ryan BM, O'donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 35(7), 553-562 (2009).
11. Mera S, Magnusson M, Tarkowski A, Bokarewa M. Extracellular survivin up-regulates adhesion molecules on the surface of leukocytes changing their reactivity pattern. J. Leukoc. Biol. 83(1), 149-155 (2008).
12. Li F. Survivin study: what is the next wave? J. Cell. Physiol. 197(1), 8-29 (2003).
13. Xu Y, Fang F, Ludewig G, Jones G, Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 23(7), 419-429 (2004).
14. Jang JS, Kim KM, Kang KH et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60(1), 31-39 (2008).
15. Wagner M, Schmelz K, Dorken B, Tamm I. Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk. Res. 32(7), 1054-1060 (2008).
16. Yang X, Xiong G, Chen X et al. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 135(10), 1341-1349 (2009).
17. Malik F, Ranganathan P. Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. Pharmacogenomics 14(3), 305-314 (2013).
18. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964-975 (2010).
19. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73(3), 492-509 (2013).
20. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62(9), 2569-2581 (2010).
21. Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur. J. Clin. Pharmacol. 64(11), 1057-1068 (2008).
22. Fransen J, Van Riel PL. The disease activity score and the EULAR response criteria. Rheum. Dis. Clin. North Am. 35(4), 745-757, vii-viii (2009).
23. Van Riel PL, Van Gestel AM. Clinical outcome measures in rheumatoid arthritis. Ann. Rheum. Dis. 59(Suppl. 1), i28-i31 (2000).
24. Sherry ST, Ward MH, Kholodov M et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29(1), 308-311 (2001).
25. Hmeljak J, Erculj N, Dolzan V, Kern I, Cor A. BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients. J. Cancer Res. Clin. Oncol. 137(11), 1641-1651 (2011).
26. Upadhyay R, Khurana R, Kumar S, Ghoshal UC, Mittal B. Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann. Surg. Oncol. 18(3), 880-887 (2011).
27. Senapati S, Singh S, Das M et al. Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation. Pharmacogenet. Genomics 24(4), 211-219 (2014).